Human Genome Sciences will start clinical trials with anti-CCR5 monoclonal antibody.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D004345:Drug Industry; D006801:Humans; D019713:Receptors, CCR5 / Q000276:immunology*
D000911:Antibodies, Monoclonal; D019713:Receptors, CCR5